CACNA1D-Related Channelopathies: From Hypertension to Autism
Handbook of Experimental Pharmacology · 2023
DOI: 10.1007/164_2022_626 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Handbook of Experimental Pharmacology, 2023. Verfasst von Nadine J Ortner. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Institute of Pharmacy, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Aus…. Hauptthemen laut MEDLINE: Autistic Disorder, Channelopathies, Hypertension. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 147 Literaturangaben.
Abstract (Originalsprache)
Tightly controlled Ca2+ influx through voltage-gated Ca2+ channels (Cavs) is indispensable for proper physiological function. Thus, it is not surprising that Cav loss and/or gain of function have been implicated in human pathology. Deficiency of Cav1.3 L-type Ca2+ channels (LTCCs) causes deafness and bradycardia, whereas several genetic variants of CACNA1D, the gene encoding the pore-forming α1 subunit of Cav1.3, have been linked to various disease phenotypes, such as hypertension, congenital hypoglycemia, or autism. These variants include not only common polymorphisms associated with an increased disease risk, but also rare de novo missense variants conferring high risk. This review provides a concise summary of disease-associated CACNA1D variants, whereas the main focus lies on de novo germline variants found in individuals with a neurodevelopmental disorder of variable severity. Electrophysiological recordings revealed activity-enhancing gating changes induced by these de novo variants, and tools to predict their pathogenicity and to study the resulting pathophysiological consequences will be discussed. Despite the low number of affected patients, potential phenotype-genotype correlations and factors that could impact the severity of symptoms will be covered. Since increased channel activity is assumed as the disease-underlying mechanism, pharmacological inhibition could be a treatment option. In the absence of Cav1.3-selective blockers, dihydropyridine LTCC inhibitors clinically approved for the treatment of hypertension may be used for personalized off-label trials. Findings from in vitro studies and treatment attempts in some of the patients seem promising as outlined. Taken together, due to advances in diagnostic sequencing techniques the number of reported CACNA1D variants in human diseases is constantly rising. Evidence from in silico, in vitro, and in vivo disease models can help to predict the pathogenic potential of such variants and to guide diagnosis and treatment in the clinical practice when confronted with patients harboring CACNA1D variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Institute of Pharmacy, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria. Nadine.ortner@uibk.ac.at.
ORCID-Profile: Nadine J Ortner
Zitieren
APA
Ortner, N. J. (2023). CACNA1D-Related Channelopathies: From Hypertension to Autism. Handbook of Experimental Pharmacology. https://doi.org/10.1007/164_2022_626
Vancouver
Ortner NJ. CACNA1D-Related Channelopathies: From Hypertension to Autism. Handbook of Experimental Pharmacology. 2023. doi:10.1007/164_2022_626
BibTeX
@article{Ortner2023,
author = {Ortner, Nadine J},
title = {CACNA1D-Related Channelopathies: From Hypertension to Autism},
journal = {Handbook of Experimental Pharmacology},
year = {2023},
doi = {10.1007/164_2022_626}
}
EUVIMED